UM  > 健康科學學院
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells
Vazquez-Ortiz G.2; Chisholm C.2; Xu X.2; Lahusen T.J.2; Li C.2; Sakamuru S.1; Huang R.1; Thomas C.J.1; Xia M.1; Deng C.2
2014-06-24
Source PublicationBreast Cancer Research
ISSN1465542X 14655411
Volume16Issue:3
Abstract

Introduction: Breast cancer is a devastating disease that results in approximately 40,000 deaths each year in the USA. Current drug screening and chemopreventatitive methods are suboptimal, due in part to the poor specificity of compounds for cancer cells. Poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi)-mediated therapy is a promising approach for familial breast cancers caused by mutations of breast cancer-associated gene-1 and -2 (BRCA1/2), yet drug resistance frequently occurs during the treatment. Moreover, PARPis exhibit very little effect on cancers that are proficient for DNA repair and clinical efficacy for PARPis as single-agent therapies has yet to be illustrated.Methods: Using a quantitative high-throughput screening approach, we screened a library containing 2,816 drugs, most of which are approved for human or animal use by the Food and Drug Administration (FDA) or other countries, to identify compounds that sensitize breast cancer cells to PARPi. After initial screening, we performed further cellular and molecular analysis on lestaurtinib, which is an orally bioavailable multikinase inhibitor and has been used in clinical trials for myeloproliferative disorders and acute myelogenous leukemia.Results: Our study indicated that lestaurtinib is highly potent against breast cancers as a mono-treatment agent. It also strongly enhanced the activity of the potent PARPi AG14361 on breast cancer cell growth both in vitro and in vivo conditions. The inhibition of cancer growth is measured by increased apoptosis and reduced cell proliferation. Consistent with this, the treatment results in activation of caspase 3/7, and accumulation of cells in the G2 phase of the cell cycle, irrespective of their BRCA1 status. Finally, we demonstrated that AG14361 inhibits NF-κB signaling, which is further enhanced by lestaurtinib treatment.Conclusions: Lestaurtinib amplifies the ability of the PARP1 inhibitor AG14361 to kill BRCA1 mutant and wild-type breast cancer cells, at least in part, by inhibiting NF-κB signaling. Each of these drugs has been approved for clinical trials for several different cancers, thus, their combination treatment should be applicable for a breast cancer trial in the future. © 2014 Vazquez-Ortiz et al.; licensee BioMed Central Ltd.

DOI10.1186/bcr3682
URLView the original
Indexed BySCI
Language英语
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000349083900023
Fulltext Access
Citation statistics
Cited Times [WOS]:8   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorDeng C.
Affiliation1.National Center for Advancing Translational Sciences
2.National Institute of Diabetes and Digestive and Kidney Diseases
Recommended Citation
GB/T 7714
Vazquez-Ortiz G.,Chisholm C.,Xu X.,et al. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells[J]. Breast Cancer Research,2014,16(3).
APA Vazquez-Ortiz G..,Chisholm C..,Xu X..,Lahusen T.J..,Li C..,...&Deng C..(2014).Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Breast Cancer Research,16(3).
MLA Vazquez-Ortiz G.,et al."Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells".Breast Cancer Research 16.3(2014).
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Vazquez-Ortiz G.]'s Articles
[Chisholm C.]'s Articles
[Xu X.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Vazquez-Ortiz G.]'s Articles
[Chisholm C.]'s Articles
[Xu X.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Vazquez-Ortiz G.]'s Articles
[Chisholm C.]'s Articles
[Xu X.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.